Stem Cells Used to Succesfully treat Type 2 Diabetes

The report details a study that involved the treatment of a type 2 diabetic (T2D) patient using personalized endoderm stem cell-derived islet tissues (E-islets). The patient, a 59-year-old man with a long history of T2D and poor glycemic control following a kidney transplant, underwent an intrahepatic implantation of E-islets. These E-islets were generated from the patient's own endoderm stem cells (EnSCs) through a series of carefully controlled stages under GMP conditions. The major objective was to evaluate the safety and efficacy of E-islet transplantation in restoring insulin secretion and improving glycemic control. The clinical procedure was executed through a percutaneous transhepatic portal vein transplantation, delivering 1.2 million IEQs of E-islets. Over a follow-up period of 116 weeks, comprehensive monitoring was performed using a 24-hour real-time continuous glucose monitoring system. Key observations included significant improvements in glycemic control, as indicated by the decline in mean amplitude of glycemic excursion (MAGE) and an increase in the time-in-target-range (TITR). Notably, there were no occurrences of severe hypoglycemia or hyperglycemia during the follow-up period, and the patient's insulin requirements were completely withdrawn by week 11 post-transplant. The study's major findings demonstrated that the autologous E-islets were well-tolerated, with no tumor formation or severe adverse events. The patient experienced improvements in fasting and post-meal glucose levels, evidenced by reduced hemoglobin A1c levels and increased fasting C-peptide levels. These outcomes indicate the potential of stem cell-derived islet tissues to functionally replace impaired islets in T2D patients, offering a promising therapeutic approach for insulin-dependent diabetes. In summary, this pilot study highlights the feasibility and effectiveness of using autologous E-islets for treating T2D patients with impaired islet function. The results provide the first clinical evidence that personalized stem cell-derived islet tissue can significantly improve glycemic control and reduce the need for exogenous insulin. Future research is recommended to expand the application of this therapy to other types of diabetes and to explore the development of universal islets for broader clinical use. Contact Beike Cell Therapy today, for information on Stem Cell Therapy for Diabetes